Sonoma Pharmaceuticals, Inc. short interest in 2023
In 2023, Sonoma Pharmaceuticals, Inc.'s disclosed short interest ran from 1.57% of shares outstanding on 13 Jan 2023 to 1.46% on 29 Dec 2023, a change of -0.11 percentage points. The year's high was 4.80% on 31 Mar 2023 and its low 0.55% on 15 Nov 2023, averaging 1.65% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 3.76 days on 31 May 2023. Full history: Sonoma Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.57% (13 Jan 2023)
- End of year
- 1.46% (29 Dec 2023)
- Change
- -0.11 pp
- High
- 4.80% (31 Mar 2023)
- Low
- 0.55% (15 Nov 2023)
- Average
- 1.65%
- Highest days to cover
- 3.76 (31 May 2023)
- SEC filings marked
- 4
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.57% | 1.03 | |
| 15 Feb 2023 | 2.36% | 1.00 | 10-Q filed |
| 28 Feb 2023 | 2.01% | 1.71 | |
| 15 Mar 2023 | 3.18% | 1.00 | |
| 31 Mar 2023 | 4.80% | 1.00 | |
| 14 Apr 2023 | 3.59% | 2.59 | |
| 28 Apr 2023 | 2.72% | 3.62 | |
| 15 May 2023 | 1.63% | 2.45 | |
| 31 May 2023 | 1.76% | 3.76 | |
| 30 Jun 2023 | 1.66% | 1.44 | 10-K filed |
| 14 Jul 2023 | 1.07% | 1.77 | |
| 31 Jul 2023 | 0.76% | 1.74 | |
| 15 Aug 2023 | 0.58% | 1.20 | 10-Q filed |
| 31 Aug 2023 | 0.83% | 2.11 | |
| 15 Sep 2023 | 0.97% | 2.54 | |
| 29 Sep 2023 | 0.70% | 1.24 | |
| 13 Oct 2023 | 0.81% | 3.73 | |
| 31 Oct 2023 | 0.94% | 1.00 | |
| 15 Nov 2023 | 0.55% | 1.00 | 10-Q filed |
| 30 Nov 2023 | 0.63% | 1.00 | |
| 29 Dec 2023 | 1.46% | 1.00 |
See also: Sonoma Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.